TG Therapeutics (NASDAQ:TGTX) Posts Earnings Results

Key Points

• TG Therapeutics reported quarterly EPS of $0.35, missing consensus by $0.02, while revenue of $259.94 million exceeded expectations of $245.47 million.
• Analysts’ consensus rating is Moderate Buy, with an average price target of $63; recent targets include B. Riley’s $86 and HC Wainwright’s $78.
• Director Laurence Charney sold 5,000 shares for about $274,800, reducing his ownership by 2.88%; insiders collectively own 8.87% of the company.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) announced its earnings results on Monday. The biopharmaceutical company reported $0.35 EPS for the quarter, missing the consensus estimate of $0.37 by ($0.02), FiscalAI reports. TG Therapeutics had a return on equity of 73.49% and a net margin of 55.22%. The firm had revenue of $259.94 million for the quarter, compared to the consensus estimate of $245.47 million.

TG Therapeutics Price Performance

NASDAQ TGTX opened at $59.83 on Monday. The stock's 50-day moving average price is $55.80 and its two-hundred day moving average price is $44.50. The company has a current ratio of 4.27, a quick ratio of 3.72 and a debt-to-equity ratio of 1.23. The company has a market cap of $9.16 billion, a PE ratio of 21.84, a PEG ratio of 2.53 and a beta of 1.89. TG Therapeutics has a 1 year low of $26.76 and a 1 year high of $63.60.

Insider Buying and Selling

In other TG Therapeutics news, Director Laurence Charney sold 5,000 shares of the firm's stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $54.96, for a total value of $274,800.00. Following the completion of the transaction, the director directly owned 168,640 shares in the company, valued at $9,268,454.40. This trade represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 8.87% of the company's stock.

Analyst Upgrades and Downgrades

TGTX has been the subject of several recent research reports. Weiss Ratings raised shares of TG Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a research note on Wednesday. B. Riley Financial lifted their price target on shares of TG Therapeutics from $55.00 to $86.00 and gave the stock a "buy" rating in a research report on Monday, July 27th. HC Wainwright reaffirmed a "buy" rating and issued a $78.00 price target on shares of TG Therapeutics in a report on Tuesday, September 1st. Zacks Research upgraded TG Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, November 4th. Finally, JPMorgan Chase & Co. increased their price objective on TG Therapeutics from $65.00 to $72.00 and gave the company an "overweight" rating in a research report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $63.00.

About TG Therapeutics

TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, including autoimmune disorders and blood cancers. Its research has centered on therapies that target B cells, a type of immune cell involved in these conditions.

The company's marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved in the United States to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics also has investigated other drug candidates and combinations for immune-related and hematologic diseases.

Headquartered in New York, TG Therapeutics serves patients in the United States and has expanded BRIUMVI's availability into international markets, including Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.